TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23852695

Group type: EXPERIMENTAL
Intervention: Tanezumab 10 mg + Diclofenac Sustained Release (DSR) 75 mg
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg + Diclofenac Sustained Release (DSR) 75 mg
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg + Diclofenac Sustained Release (DSR) 75 mg
Number of subjects: 604

Group type: COMPARATOR
Intervention: Placebo + Diclofenac Sustained Release (DSR) 75 mg
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Tanezumab + Diclofenac Sustained Release (DSR)
Number of subjects: 604
Study: 22892374

Group type: EXPERIMENTAL
Intervention: Telemedicine device
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional approach
Number of subjects: 40
Study: 20137768

Group type: EXPERIMENTAL
Intervention: Test tablets (Gen‐Nifedipine extended release)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Reference tablets (Adalat XL)
Number of subjects: 26
Study: 18030231

Group type: EXPERIMENTAL
Intervention: AtTGA stick
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: AtTGA/AGA stick
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: IgA AtTGA/AGA stick
Number of subjects: 185
Study: 16084881

Group type: EXPERIMENTAL
Intervention: GnRH agonist
Number of subjects: 55

Group type: COMPARATOR
Intervention: GnRH antagonist
Number of subjects: 55
Study: 11487990

Group type: EXPERIMENTAL
Intervention: Stage-based alcohol preventive intervention
Number of subjects: 650

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 650
Study: 9725755

Group type: EXPERIMENTAL
Intervention: Lorazepam 0.038 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam 0.3 mg/kg
Number of subjects: 0
Study: 8131256

Group type: EXPERIMENTAL
Intervention: Routine malaria chemoprophylaxis
Number of subjects: 0
Study: 2661232

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (Rocephin)
Number of subjects: 883

Group type: COMPARATOR
Intervention: Cefamandole
Number of subjects: 883
Study: 30218764

Group type: EXPERIMENTAL
Intervention: Prospective screening program for C. difficile prior to cystectomy with prophylactic treatment using metronidazole.
Number of subjects: 766

Group type: COMPARATOR
Intervention: Historical matched controls (no screening program).
Number of subjects: 766
Study: 28179024

Group type: EXPERIMENTAL
Intervention: 4-monthly albendazole treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single annual albendazole treatment
Number of subjects: 0
Study: 25623680

Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22799582

Group type: EXPERIMENTAL
Intervention: Cued recall of targets and mediators
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cued recall of mediators
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Reporting the wrong target word
Number of subjects: 49
Study: 22303641

Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone
Number of subjects: 190

Group type: COMPARATOR
Intervention: 0.1 mg kg(‐1) morphine
Number of subjects: 190
Study: 19050671

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 368

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Leptin quartiles
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Adiponectin
Number of subjects: 368
Study: 16917560

Group type: EXPERIMENTAL
Intervention: Ampicillin/Sulbactan
Number of subjects: 102

Group type: COMPARATOR
Intervention: Amoxicillin/Clavulanate
Number of subjects: 102
Study: 15331035

Group type: EXPERIMENTAL
Intervention: E-mail communication preference (LSE)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Face-to-face communication preference (HSE)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: E-mail preference under high rejection scenarios
Number of subjects: 265
Study: 14589782

Group type: EXPERIMENTAL
Intervention: malingerers
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: malingerers-with-warnings
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: warning-only
Number of subjects: 60

Group type: COMPARATOR
Intervention: control
Number of subjects: 60
Study: 9645635

Group type: EXPERIMENTAL
Intervention: 0.75% topical metronidazole gel
Number of subjects: 113

Group type: COMPARATOR
Intervention: topical metronidazole vehicle gel (placebo)
Number of subjects: 113
Study: 7836628

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (MgO)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control studies (no magnesium supplementation)
Number of subjects: 5
Study: 2841172

Group type: EXPERIMENTAL
Intervention: Trimethoprim-polymyxin B sulphate ophthalmic ointment (5 mg/g and 10,000 units/g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chloramphenicol ophthalmic ointment (1%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparison of both treatments
Number of subjects: 0
Study: 29660670

Group type: EXPERIMENTAL
Intervention: Tilt group (passive tilting added to standardized rehabilitation therapy)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group (standardized rehabilitation therapy alone)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Tilt group
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 145
Study: 28176423

Group type: EXPERIMENTAL
Intervention: Classical foot massage
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care control
Number of subjects: 60
Study: 25841654

Group type: EXPERIMENTAL
Intervention: Enhanced CBM-errors (targeting cognitive errors plus prospective cognition)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard CBM-errors (targeting cognitive errors without prospective cognition)
Number of subjects: 80
Study: 23529918

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training (AET) + Antihypertensive Drugs (ADs)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Antihypertensive Drugs (ADs) alone
Number of subjects: 120
Study: 21440882

Group type: EXPERIMENTAL
Intervention: Auriculopuncture and ultralow‐power laserpuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (sham stimulation)
Number of subjects: 0
Study: 18326592

Group type: EXPERIMENTAL
Intervention: TFAs from natural sources (11-12 g/d, approximately 5% of daily energy)
Number of subjects: 46

Group type: COMPARATOR
Intervention: TFAs from industrially produced sources
Number of subjects: 46
Study: 16566972

Group type: EXPERIMENTAL
Intervention: Antibiotics and prostatic massage (group 1: n = 17)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Antibiotics alone (group 2: n = 20)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Antibiotics and prostatic massage (group 3: n = 25)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Antibiotics alone (group 4: n = 19)
Number of subjects: 81
Study: 11902250

Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemofiltration (CVVH) at 2 L/hr for 48 hrs
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no hemofiltration)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemofiltration (CVVH)
Number of subjects: 24
Study: 10458528

Group type: EXPERIMENTAL
Intervention: Auscultation with the aid of an FHR meter
Number of subjects: 30

Group type: COMPARATOR
Intervention: Auscultation by counting alone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Visual assessment
Number of subjects: 30
Study: 7597270

Group type: COMPARATOR
Intervention: Lateral body position (right and left lateral decubitus)
Number of subjects: 30
Study: 1693316

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with ifosfamide, cisplatin, and bleomycin (BIP) prior to radiotherapy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 66
Study: 38704

Group type: EXPERIMENTAL
Intervention: Halothane (Group I)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Neuroleptanalgesia (Group II)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 25
Study: 6749634

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid for dissolution of gallstones
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Continuing chenotherapy
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Choleitholytic therapy
Number of subjects: 22
Study: 30513347

Group type: EXPERIMENTAL
Intervention: Single-site bolus NGF injection (5 µg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Spatially distributed low-dose NGF injections (1 µg, 4 cm distance)
Number of subjects: 20
Study: 30048048

Group type: EXPERIMENTAL
Intervention: Moderately rough implant (Sa: 1.3 μm)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Hybrid surface implant (moderately rough implant body [Sa: 1.3 μm] and minimally rough implant neck [Sa: 0.9 μm])
Number of subjects: 21
Study: 26205305

Group type: EXPERIMENTAL
Intervention: Process-based cognitive training (pb-CT) combined with reminiscence therapy (RT) for 3 months
Number of subjects: 348
Study: 24254057

Group type: EXPERIMENTAL
Intervention: Barley oil T3 (nanoemulsified)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Palm oil T3 (nanoemulsified)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Barley oil supplements
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Palm oil supplements
Number of subjects: 100
Study: 22851543

Group type: EXPERIMENTAL
Intervention: Extracellular volume fraction (ECV) measured using gadolinium contrast in patients
Number of subjects: 802

Group type: COMPARATOR
Intervention: Extracellular volume fraction (ECV) in healthy volunteers
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: Extracellular volume fraction (ECV) in patients
Number of subjects: 802
Study: 20006641

Group type: EXPERIMENTAL
Intervention: Free weights
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Elastic tubing
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control
Number of subjects: 108
Study: 17324686

Group type: EXPERIMENTAL
Intervention: IFN-alpha treatment
Number of subjects: 49
Study: 16286543

Group type: EXPERIMENTAL
Intervention: Topiramate (target dose, 400 mg/d in adults)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 12098088

Group type: EXPERIMENTAL
Intervention: Kogenate®
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinate®
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ReFacto®
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kogenate FS®
Number of subjects: 0
Study: 10210384

Group type: EXPERIMENTAL
Intervention: 20 mg furosemide
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 20 mg furosemide on second visit
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 20 mg furosemide on first visit
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Diuretic use
Number of subjects: 99
Study: 8572212

Group type: EXPERIMENTAL
Intervention: Octreotide (100 micrograms)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 2093379

Group type: EXPERIMENTAL
Intervention: New semiautomated algorithm to quantify Holter-detected myocardial ischemia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simple measurements (number and duration of ischemic events)
Number of subjects: 0
Study: 350497

Group type: EXPERIMENTAL
Intervention: 3 g salsalate per day
Number of subjects: 20

Group type: COMPARATOR
Intervention: 3.6 g soluble aspirin per day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: salsalate
Number of subjects: 20

Group type: COMPARATOR
Intervention: aspirin
Number of subjects: 20
Study: 31858128

Group type: EXPERIMENTAL
Intervention: Tubaramure program (food rations including corn-soy blend and micronutrient-fortified vegetable oil)
Number of subjects: 11906

Group type: EXPERIMENTAL
Intervention: Tubaramure program
Number of subjects: 11906

Group type: EXPERIMENTAL
Intervention: Postprogram effects of Tubaramure program
Number of subjects: 11906
Study: 31289313

Group type: EXPERIMENTAL
Intervention: Optical biometer SS‐OCT scans
Number of subjects: 749

Group type: COMPARATOR
Intervention: Conventional SD‐OCT
Number of subjects: 749
Study: 28445871

Group type: EXPERIMENTAL
Intervention: Resolute Integrity stents (n = 481)
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: Promus Element stents (n = 476)
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: High-risk patients
Number of subjects: 957
Study: 25916341

Group type: EXPERIMENTAL
Intervention: HZ/su vaccine
Number of subjects: 15411

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15411
Study: 23850262

Group type: EXPERIMENTAL
Intervention: Elevated Lipoprotein-B (Lp-B)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Lp-B:C
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Apolipoprotein B (ApoB)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Apo-AII
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: ApoC-III
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: ApoC-III in VLDL (heparin-manganese precipitate)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: ApoC-III in HDL (heparin-manganese supernatant)
Number of subjects: 436
Study: 20625344

Group type: EXPERIMENTAL
Intervention: Sound-activated light device present (turned on)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sound-activated light device present (turned off)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No device present
Number of subjects: 0
Study: 19060001

Group type: EXPERIMENTAL
Intervention: ASDAS (Ankylosing Spondylitis Disease Activity Score)
Number of subjects: 2

Group type: COMPARATOR
Intervention: BASDAI (Bath Ankylosing Spondylitis Disease Activity Index)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: ASDAS version including back pain, duration of morning stiffness, patient global assessment, peripheral joint complaints and CRP
Number of subjects: 2
Study: 17241101

Group type: COMPARATOR
Intervention: Inhaled β2-agonists (formoterol, salbutamol, salmeterol, terbutaline)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Supratherapeutic doses of salbutamol (800-1200μg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Oral administration of salbutamol
Number of subjects: 19
Study: 15570242

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH, 450 IU/kg/24 hr)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Subcutaneous dalteparin, 100 IU/kg given twice at a 12-hr interval
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Subcutaneous dalteparin, 200 IU/kg given once
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline-solution infusion
Number of subjects: 8
Study: 12002786

Group type: EXPERIMENTAL
Intervention: Diet low in calcium and exogenous microparticles
Number of subjects: 0
Study: 10228904

Group type: EXPERIMENTAL
Intervention: CA 125 screening with a cutoff value of 30 U/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasonography as a second-line test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mathematical algorithm analyzing rates of change of CA 125
Number of subjects: 0

Group type: COMPARATOR
Intervention: Screening strategies incorporating CA 125
Number of subjects: 0
Study: 7611754

Group type: EXPERIMENTAL
Intervention: Intraarterial infusion of Epi‐adriamycin 30‐40 mg/body and CDDP 100 mg/body via reservoir every two weeks post‐operatively (group R)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: One-shot infusion of Epi‐adriamycin or adriamycin (group O)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (group N)
Number of subjects: 118
Study: 2363531

Group type: EXPERIMENTAL
Intervention: Alfentanil 3 micrograms/kg
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Alfentanil 15 micrograms/kg
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Alfentanil 10 micrograms/kg
Number of subjects: 95
Study: 380635

Group type: EXPERIMENTAL
Intervention: Extended-wear soft lenses
Number of subjects: 0
Study: 30753368

Group type: EXPERIMENTAL
Intervention: Human rotavirus vaccine (HRV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no HRV)
Number of subjects: 0
Study: 29976293

Group type: EXPERIMENTAL
Intervention: High IL-8 levels measured immediately after PCI and at day 1
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: High IL-8 levels at day 1
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: IL-8 levels in the highest quartile measured at all sampling points
Number of subjects: 258
Study: 27374016

Group type: EXPERIMENTAL
Intervention: Neck-specific exercises
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Neck-specific exercises with behavioral approach
Number of subjects: 216

Group type: COMPARATOR
Intervention: General physical activity
Number of subjects: 216
Study: 23981528

Group type: EXPERIMENTAL
Intervention: Intracameral mydriatics
Number of subjects: 56

Group type: COMPARATOR
Intervention: Topical mydriatics
Number of subjects: 56
Study: 21642470

Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bilastine 100 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg with Ketoconazole 400 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (active control)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 19473072

Group type: EXPERIMENTAL
Intervention: Exercise program with low-level laser therapy (LLLT); 904-nm Ga-As laser in continuous mode, power density 130 mW/cm², dose 0.585 J/point.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Exercise program with polarized polychromatic non-coherent light (Bioptron 2); administered perpendicularly to the lateral epicondyle at three points for 6 min at each position.
Number of subjects: 50
Study: 17768457

Group type: EXPERIMENTAL
Intervention: Flow-mediated vasodilation (FMD)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Typical anginal chest pain
Number of subjects: 92

Group type: COMPARATOR
Intervention: Exercise stress test
Number of subjects: 92

Group type: COMPARATOR
Intervention: Myocardial perfusion imaging (MPI)
Number of subjects: 92
Study: 15345790

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 11136139

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg etomidate
Number of subjects: 31

Group type: COMPARATOR
Intervention: 0.05‐0.1 mg/kg midazolam (control group)
Number of subjects: 31
Study: 9633671

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (tryptophan-free amino acid beverage plus amino acid capsules)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Catecholamine depletion (alpha-methyl-paratyrosine)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham depletion (Diphenhydramine hydrochloride)
Number of subjects: 16
Study: 7935995

Group type: EXPERIMENTAL
Intervention: Busulphan treatment
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Blast crisis phase
Number of subjects: 28

Group type: COMPARATOR
Intervention: Initial phase at diagnosis
Number of subjects: 28

Group type: COMPARATOR
Intervention: Remission phase
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Correlation between red cell ferritin and hemoglobin (Hb)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Remission after busulphan treatment
Number of subjects: 28
Study: 3346570

Group type: EXPERIMENTAL
Intervention: Q fever vaccine
Number of subjects: 13
Study: 28692567

Group type: EXPERIMENTAL
Intervention: Forward digit span training for 5 weeks
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Backward digit span training for 5 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Overall comparison with children with normal hearing
Number of subjects: 44
Study: 26993648

Group type: EXPERIMENTAL
Intervention: Green-dyed liquids
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-dyed liquids
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Large volumes of thin liquids (90 ml)
Number of subjects: 40
Study: 24229481

Group type: EXPERIMENTAL
Intervention: Manualized psychodynamic therapy (PDT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Waiting list/treatment-as-usual (WL/TAU)
Number of subjects: 66
Study: 23537708

Group type: EXPERIMENTAL
Intervention: Etoposide in combination with low-dose CAG (E-CAG)
Number of subjects: 228

Group type: COMPARATOR
Intervention: CAG without etoposide (CAG)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Patients with CR who underwent allogenic hematopoietic stem cell transplantation (allo-HSCT)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Patients without allo-HSCT
Number of subjects: 228
Study: 20959071

Group type: EXPERIMENTAL
Intervention: Filling-fat group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-filling-fat group
Number of subjects: 60
Study: 18188694

Group type: EXPERIMENTAL
Intervention: Lapatinib 1,250 mg/day plus capecitabine 2,000 mg/m2 days 1-14 of a 21-day cycle
Number of subjects: 399

Group type: COMPARATOR
Intervention: Capecitabine 2,500 mg/m2 on the same schedule
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Lapatinib plus capecitabine
Number of subjects: 399
Study: 16896785

Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Amlodipine-atorvastatin (10 mg + 20 mg)
Number of subjects: 50
Study: 14652260

Group type: EXPERIMENTAL
Intervention: Constructing speed bumps
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: Volunteering as a crossing guard
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: Attending a neighbourhood meeting
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: Attending a safety workshop
Number of subjects: 723
Study: 10992375

Group type: EXPERIMENTAL
Intervention: Indwelling catheter replacement before antimicrobial therapy
Number of subjects: 54

Group type: COMPARATOR
Intervention: No catheter replacement before antimicrobial therapy
Number of subjects: 54
Study: 9463121

Group type: EXPERIMENTAL
Intervention: Pulfrich's pendulum test
Number of subjects: 39
Study: 7514237

Group type: EXPERIMENTAL
Intervention: Total mortality
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Time to death, progression to severe/resistant heart failure, reinfarction or stroke
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Hospitalization and mode of death
Number of subjects: 2000
Study: 3080269

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ibuprofen + Ethanol
Number of subjects: 6

Group type: COMPARATOR
Intervention: Ethanol
Number of subjects: 6
Study: 29447782

Group type: EXPERIMENTAL
Intervention: Drug-eluting balloon (DEB)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Second-generation everolimus-eluting stent (DES)
Number of subjects: 172